Short Interest in Pluri Inc. (NASDAQ:PLUR) Decreases By 14.0%

Pluri Inc. (NASDAQ:PLUR) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 25,800 shares, a decline of 14.0% from the February 13th total of 30,000 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily volume of 12,700 shares, the days-to-cover ratio is currently 2.0 days.

Pluri Price Performance

PLUR traded up $0.02 on Wednesday, hitting $4.43. 2,234 shares of the company’s stock were exchanged, compared to its average volume of 18,073. Pluri has a fifty-two week low of $4.07 and a fifty-two week high of $8.40. The company has a current ratio of 5.04, a quick ratio of 5.04 and a debt-to-equity ratio of 4.44. The firm has a 50-day moving average price of $4.46 and a 200-day moving average price of $4.82. The stock has a market cap of $30.96 million, a price-to-earnings ratio of -0.79 and a beta of 1.76.

Pluri (NASDAQ:PLUR) last announced its earnings results on Tuesday, February 11th. The company reported ($0.53) earnings per share (EPS) for the quarter. Pluri had a negative return on equity of 2,778.13% and a negative net margin of 3,551.49%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pluri stock. Renaissance Technologies LLC lifted its stake in shares of Pluri Inc. (NASDAQ:PLUR) by 38.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,025 shares of the company’s stock after acquiring an additional 9,400 shares during the period. Renaissance Technologies LLC owned 0.61% of Pluri worth $145,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 16.59% of the company’s stock.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.